-
Cii Tech Secures Tens of Millions in Pre-Series A Funding for Mass Spectrometry
•
China Innovation Instrument (Cii Tech), a life sciences instrument maker based in Ningbo, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The funding was solely led by a fund from Oak Acorn Capital. The proceeds will be allocated towards the research and development of…
-
TechnoDerma Raises Series A+ Funding to Advance Dermatology Pipeline
•
TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funding was led by Chengdu Biological City No. 1 Equity Investment Fund Partnership and Chengdu High-tech New Economy Venture Capital. The proceeds will be used…
-
Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma
•
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study of its Category 1 chemical drug KC1036. The study will assess the efficacy and safety of KC1036 in combination with docetaxel for the treatment of…
-
Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study
•
Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States, and China, has announced receiving approval from the US Food and Drug Administration (FDA) to conduct an open-label, multi-center Phase I study of its monoclonal antibody (mAb) HBM1020. The study will assess the safety, tolerability,…
-
Porton Pharma Solutions to Invest EUR 50 Million in Slovenia Bio-Industry Park
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions is set to establish a bio-industry park in Slovenia, marking a significant expansion of its presence in the European market. The project will involve an investment of EUR 50 million (USD 54.2 million) and will include the construction of an…
-
ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced a strategic partnership with compatriot firms Shaanxi Pharmaceutical Holding Group Co., Ltd and Shaanxi Pharmaceutical Holding Pai Ang. The collaboration aims to leverage the respective resources and expertise of the three companies to enhance drug…
-
Syneos Health Partners with Fosun Pharma to Commercialize Serplulimab in US
•
US-based Syneos Health (Nasdaq: SYNH) has revealed a strategic partnership with Fosun Pharma USA Inc., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196), focused on the anti-programmed death-1 (PD-1) inhibitor serplulimab. Syneos will provide full commercial support in the United States for serplulimab’s development as…
-
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA) has approved its iGlarLixi (insulin glargine, lixisenatide) for use in adult patients with type 2 diabetes who have poor blood glucose control. This approval marks a significant step in expanding treatment options for patients struggling…
